CD8A and neoplasm: Among the 46 patients with post-baseline tumor assessment, the median duration of treatment was similar in the CD8+ cell > 20% and CD8+ cell = 10–20% subgroups (10.0 and 9.8 months, respectively) (Fig. S2).